Maitreya Medicare (NSE:MAITREYA) Research & Development: ₹0.0 Mil (TTM As of Sep. 2023)


NSE:MAITREYA Maitreya Medicare Ltd NSE:MAITREYA
18 GF Score
Price ₹137.85
View Full Analysis

What is Maitreya Medicare Research & Development?

Maitreya Medicare NSE:MAITREYA -0.11% 18 Research & Development is ₹0.0 Mil as of Sep. 2023. GuruFocus rates NSE:MAITREYA with a GF Score™ of 18/100.

Research & Development is the aggregate amount of research and development expenses during the year. Maitreya Medicare's Research & Development for the six months ended in Sep. 2023 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was ₹0.0 Mil.

Maitreya Medicare  (NSE:MAITREYA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Maitreya Medicare Research & Development Related Terms

Maitreya Medicare Research & Development Historical Data

* Premium members only.

The historical data trend for Maitreya Medicare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maitreya Medicare Research & Development Chart

Maitreya Medicare Annual Data
Trend Mar21 Mar22 Mar23
Research & Development
0.00 0.00 0.00

Maitreya Medicare Semi-Annual Data
Mar21 Mar22 Mar23 Sep23
Research & Development 0.00 0.00 0.00 0.00
NSE:MAITREYA
18GF Score
Maitreya Medicare Ltd NSE:MAITREYA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maitreya Medicare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Maitreya Medicare (NSE:MAITREYA) has a Research & Development of ₹0.0 Mil as of Sep. 2023. Research and development expense is the total cost for research and development activities. View historical data on Maitreya Medicare and its competitors.
Is Maitreya Medicare's Research & Development too high?
Maitreya Medicare's current Research & Development is ₹0.0 Mil. Overall, Maitreya Medicare has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Maitreya Medicare's Research & Development compare to HCA and DVA?
Maitreya Medicare's Research & Development of ₹0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Maitreya Medicare and its competitors. Maitreya Medicare's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maitreya Medicare stock overvalued right now?
Maitreya Medicare (NSE:MAITREYA) has a current Research & Development of ₹0.0 Mil. The current Research & Development is ₹0.0 Mil. Maitreya Medicare's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Maitreya Medicare (NSE:MAITREYA), the current Research & Development is ₹0.0 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maitreya Medicare Business Description

Address Nr. Someshwara Char Rasta, Udhana - Magdalla Road, Surat, GJ, IND, 395007
Maitreya Medicare Ltd is Multi Superspeciality hospital. It is a 125 bedded hospital that provides multi-disciplinary integrated healthcare services, with a focus on primary secondary & tertiary care, and also offers a comprehensive range of healthcare services across over 18 specialties and super specialties, including Cardiology, Urology, Oncology, Laparoscopic Surgery, Neurology, Neurosurgery, Spine Surgery, Nephrology including Dialysis, Gastroenterology, Gastrointestinal surgery, Cardiothoracic Surgery, Oncosurgery, Orthopedic Surgery including joint replacements and Arthroscopic surgeries, Gynecology & High-Risk Obstetrics, Hepatocellular Billary Surgery, Critical Care Medicine etc.
18GF Score

Get the complete analysis for NSE:MAITREYA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹137.85
Price